Khosla Ventures most active neurotech investor Q1 2025-Q1 2026 — three separate rounds in Somnee, Synchron, and Science Corporation
Summary
New Market Pitch's analysis of 30 disclosed neurotechnology funding rounds from Q1 2025 to Q1 2026 identified Khosla Ventures as the most active neurotechnology market investor, participating in three separate rounds — Somnee (consumer sleep neurostimulation), Synchron (endovascular BCI for communication), and Science Corporation (PRIMA retinal BCI). Khosla's three-company neurotech portfolio spans consumer wellness (Somnee), clinical communication BCI (Synchron), and sensory restoration BCI (Science Corp) — a deliberate diversification across the neurotech landscape rather than a single-thesis concentration.
Why it matters
Khosla being the most active neurotech investor across three distinct categories — consumer, clinical BCI, and sensory BCI — is a portfolio construction strategy that hedges which application wins first while maintaining conviction that neurotech as a category will be transformative. As the most active investor in the sector, Khosla has the clearest view of competitive dynamics across all three segments, giving them both early intelligence and follow-on investment advantage.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial